| 176.66 2.54 (1.46%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 207.15 | 1-year : | 241.95 |
| Resists | First : | 177.35 | Second : | 207.15 |
| Pivot price | 170.41  |
|||
| Supports | First : | 166.43 | Second : | 159.67 |
| MAs | MA(5) : | 174.96 |
MA(20) : | 168.66 |
| MA(100) : | 170.8 |
MA(250) : | 150.53 |
|
| MACD | MACD : | 1.8 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 89.6  |
D(3) : | 91.2 |
| RSI | RSI(14): 61.7 |
|||
| 52-week | High : | 179.5 | Low : | 115.97 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ IBB ] has closed below upper band by 15.4%. Bollinger Bands are 70.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 177.53 - 178.24 | 178.24 - 178.84 |
| Low: | 173.5 - 174.38 | 174.38 - 175.14 |
| Close: | 175.15 - 176.58 | 176.58 - 177.8 |
The iShares Biotechnology ETF seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector.
Sat, 11 Apr 2026
Best Biotech ETFs for 2026 and How to Invest in Them - The Motley Fool
Tue, 07 Apr 2026
XBI vs. IBB: The Biotech ETF Showdown That Analysts Say Has a Clear Winner in 2026 - 24/7 Wall St.
Thu, 02 Apr 2026
Biotech Is Holding Steady In 2026 (NASDAQ:IBB) - Seeking Alpha
Tue, 31 Mar 2026
Biotech Stocks Are Up About 35% in the Past Year and Analysts Say the Biggest Gains Are Still Ahead - 24/7 Wall St.
Sat, 21 Mar 2026
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing - Yahoo Finance
Wed, 25 Feb 2026
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|